Appropriate design of prospective studies

Journal of Clinical Oncology

Volumn 31, Issue 4, 2013, Pages 510-511

  Choi, Jung Hye ^a   Jung, Sin Ho ^b  

^a Hanyang University   (South Korea)

^b DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; TAMOXIFEN; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

BREAST CANCER; CANCER GROWTH; HUMAN; LETTER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); STUDY DESIGN; BREAST TUMOR; FEMALE; NOTE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST NEOPLASMS; FEMALE; HUMANS; RECEPTOR, ERBB-2;

EID: 84874776346     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.46.0980     Document Type: Letter

References (5)

1. Bachelot T, Bourgier C, Cropet C, et al: Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptorpositive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: A GINECO Study. J Clin Oncol 30:2718-2724, 2012
2. Baselga J, Campone M, Piccart M, et al: Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366:520-529, 2012
3. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989 (Pubitemid 19099520)
4. Jung SH: Randomized phase II trials with a prospective control. Stat Med 27:568-583, 2008
5. Wieand S, Schroeder G, O'Fallon JR: Stopping when the experimental regimen does not appear to help. Stat Med 13:1453-1458, 1994 (Pubitemid 24236197)